Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06381466 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT06381466 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 84 participants.
The verdict
NCT06381466, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of AZD0233 following single and multiple ascending dose (SAD and MAD) administration in healthy participants.
Interventions
- DRUG AZD0233
- DRUG AZD0233 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06381466
The ClinicalTrials.gov registry entry for NCT06381466 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD0233 is the first listed.
NCT06381466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06381466 about?
NCT06381466 is a clinical study titled "A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.". The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of AZD0233 following single and multiple ascending dose (SAD and MAD) administration in healthy participants.
What is the current status of trial NCT06381466?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2024-04-01. Estimated completion is 2025-12-30.
What interventions are being tested in trial NCT06381466?
The interventions under investigation include: AZD0233 (DRUG), AZD0233 Placebo (DRUG).
Who is sponsoring clinical trial NCT06381466?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.